Lorviqua (lorlatinib)

Lorviqua (lorlatinib) is a medicine indicated for the treatment of previously treated patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

The medicine is marketed in the USA under the brand name Lorbrena, and in the EU under the brand name Lorviqua. We can help you obtain Lorviqua (lorlatinib) on our website.